Market
Acquiring 60% stake in Needs Tech for 3.7 billion won to secure management control<br>Part of efforts to diversify business and secure future growth engine

Drug development company Shaperon is entering the aesthetic device market with a 3.7 billion won investment as part of its business diversification efforts.
Shaperon said in a disclosure on the 11th that it had decided to acquire 60,000 shares, representing a 60% stake, in aesthetic device seller Needs Tech for 3.7 billion won. The scheduled acquisition date is July 1, 2026, and the purchase price will be paid entirely with the company’s own funds.
The acquisition is intended to diversify the business by securing management control and establish a future growth engine. In addition to its existing drug development business based on inflammasome inhibitors, Shaperon will expand into the aesthetics sector.
Needs Tech, the acquisition target, primarily sells aesthetic devices. According to the disclosure, Needs Tech reported revenue of 17.076 billion won in 2025 and 17.741 billion won in 2024.
In connection with the stake acquisition, Shaperon had the fairness of the purchase price assessed by Dongsung Accounting Corporation, an external appraisal institution. It also entered into a call option agreement allowing it to purchase the remaining stake held by Jeon Sang-yeon, CEO of Needs Tech, in the future, establishing a mechanism to secure stable management control.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
AstraZeneca’s new myasthenia gravis drug, cligepa, approved simultaneously in U.S. and EU

Biogen Invests $411 Million in Neurodegenerative Disease Drug Development

J&J to acquire Olin for $2.9 billion, taking on Roche’s Vabysmo

Lilly acquires rare blood cancer drug startup for up to $1.5 billion, its 15th deal this year

Seawolf Secures $100 Million and Signs $1.2 Billion DNA Therapeutics Deal With Sanofi

ROKIT Healthcare to Acquire Insolvent Rehabilitation Company for 7 Billion Won, Betting on a Platform